Literature DB >> 7637246

[Clinical study of renal cell carcinoma with brain metastasis].

J Yonese, S Kawakami, T Ueda, M Tsuzuki, S Kageyama, K Yoshimura, T Yamauchi, I Fukui, T Kawai.   

Abstract

Of 130 cases with renal cell carcinoma treated at Cancer Institute Hospital from January, 1981 to December, 1992, 14 (10.6%) developed brain metastasis, 12 of whom had had preceding pulmonary metastasis. Interval between the initial treatment of the primary lesion (nephrectomy in 13, embolization in 1) and the diagnosis of brain metastasis ranged 0 to 57 months with a median of 11 months. Twelve patients had clinical symptoms such as headache, vomiting, paralysis or disturbance of consciousness. Eleven patients were treated with external beam irradiation (30-60 Gy linear accelerator). Only 3 (30%) of 10 patients with measurable lesion on CT scan achieved PR but 6 (66.7%) of 9 had symptomatic improvement. Especially, chronic intracranial hypertension such as headache and vomiting disappeared in 5 (83.3%) of 6. Average survival period and one year survival after the diagnosis of brain metastasis were 5 months and 14.3%. Although most of the patients with brain metastasis died of the progression of other organ metastasis, radiation therapy for brain metastasis was useful to palliate the agonizing symptoms.

Entities:  

Mesh:

Year:  1995        PMID: 7637246     DOI: 10.5980/jpnjurol1989.86.1287

Source DB:  PubMed          Journal:  Nihon Hinyokika Gakkai Zasshi        ISSN: 0021-5287


  2 in total

1.  Sudden cessation of respiration in a patient with a solitary metastatic focus of renal cell carcinoma in medulla oblongata.

Authors:  Baki S Albayrak; Askin Gorgulu
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

2.  Peritumoral and intratumoral hemorrhage after stereotactic radiosurgery for renal cell carcinoma metastasis to the brain.

Authors:  Fotios Kalfas; Nello Ronchini; Tomasz Tadeusz Godowicz; Paolo Cavazzani; Paolo Severi
Journal:  J Radiosurg SBRT       Date:  2011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.